Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Multiple Myeloma

Carfilzomib + Melphalan/Prednisone for Newly Diagnosed Multiple Myeloma (CLARION Study)
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Status Conditions Phase Study ID
Pending Multiple Myeloma Phase III NCT01818752
Summary

This is a Phase 3 multicenter, open-label, randomized study in transplant-ineligible subjects with newly diagnosed multiple myeloma. Subjects are randomized to receive 1 of 2 treatment regimens: Carfilzomib, Melphalan and Prednisone (CMP) or Velcade® (Bortezomib), Melphalan and Prednisone (VMP).


Investigator
Edward Libby, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Newly diagnosed symptomatic multiple myeloma
  • Transplant-ineligibility
  • Males and females ≥ 18 years of age
  • Left ventricular ejection fraction (LVEF) ≥ 40%
Exclusions (conditions that would prevent participation in this study)
  • Waldenstrom macroglobulinemia
  • Known amyloidosis
  • Plasma cell leukemia
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)
  • Significant neuropathy (Grades ≥ 2) within 14 days prior to randomization
Last Updated
April 22, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.